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PSK3
“HEALTH BENEFIT LIMITS” LIMIT TREATMENT OF PSORIASIS
AND OTHER DERMATOLOGICAL CONDITIONS
Venkat A1, Kulkarni AS2, Balkrishnan R2, Feldman SR3
1Wake Forest University, Winston-Salem, NC, USA, 2The Ohio State
University College of Pharmacy, Columbus, OH, USA, 3Wake Forest
University School of Medicine, Winston Salem, NC, USA
OBJECTIVE: Assess types and inﬂuence of health beneﬁt limits
on treatment of psoriasis and other dermatological conditions.
METHODS: Five major health insurance providers in the United
States, Kaiser, Foundation Health Plan, United Health Group,
CIGNA Corp, Aetna Inc, and AFLAC Inc. were contacted for
information regarding their health beneﬁt limits. Annual costs of
drugs were obtained from the Drug Topics Red Book 2003 for
a 70-kg participant. Age at which insurance beneﬁts would
exhaust was calculated based on different onset ages for treat-
ment costing $30,000/year and different lifetime beneﬁt limit
amounts. RESULTS: Various forms of health beneﬁt limits were
imposed by insurance companies. These companies paid a
limited amount for drugs annually, with annual caps ranging
from $1000 to $20,000. Companies had different payment poli-
cies for brand-name drugs and generic drugs. Lifetime beneﬁt
maximum for physician ofﬁce and hospital visit expenses was
another form of cap that was used. Assuming no other claims
applied, analysis indicated that a lifetime beneﬁt cap of $500,000
for treatment of psoriasis starting at age 20 years exhausted
around the age of 40 years. Furthermore, an annual cap of $1000
allowed for full coverage of only methotrexate while, annual
caps of $15,000 or less affected coverage for etanercept and efal-
izumab. For patients requiring multiple drug treatments, even
higher annual caps limited drug coverage. CONCLUSIONS:
Annual and lifetime limits were most common form of caps.
Insurance limits potentially affect access to health care as they
limit coverage of treatments for psoriasis and potentially other
conditions. It is important for physicians to be aware of the vari-
ations in insurance coverage, especially before a new treatment
option is explored. If insurance coverage was a standard ques-
tion in the doctor-patient encounter, it could arguably improve
patient compliance and outcomes.
PSK4
MEDICATION-RELATED FACTORS AFFECTING HEALTH CARE
OUTCOMES AND COSTS IN PATIENTS WITH PSORIASIS AND
ACNE IN THE UNITED STATES
Kulkarni AS1, Balkrishnan R1, Feldman SR2
1The Ohio State University College of Pharmacy, Columbus, OH,
USA, 2Wake Forest University School of Medicine, Winston Salem,
NC, USA
OBJECTIVES: Comparing relationships between health status
and costs and medication related factors in the treatment of acne
and psoriasis. METHODS: This was a cross sectional study com-
paring cohorts of acne and psoriasis patients, using the United
States Medical Expenditure Panel Survey (MEPS) 2000 database.
Patients were identiﬁed using the ICD-9 (International Classiﬁ-
cation of Diseases, 9th revision) code “706” for acne vulgaris
and “696” for psoriasis and similar conditions. ICD-9 codes for
acne/psoriasis and receipt of medication for acne/psoriasis were
used in obtaining records of medical events. Costs, demograph-
ics information, health care service utilization and clinical patient
variables were retrieved from the MEPS database. Health status
information was obtained using the EuroQOL (EQ-5D) scores
available in MEPS. Indices for medication adherence and comor-
bidities were also calculated using the data from the MEPS. Sep-
arate weighted multivariate linear regression analysis was
performed on data for approximately 5 million acne patients and
1 million psoriasis patients (weighted sample size). RESULTS:
Acne-related medication accounted for approximately 36% of
the total acne related health care costs, while psoriasis-related
medications accounted for almost 50% of the total psoriasis
related health care costs. Both acne and psoriasis patients had
an average of almost 3 annual prescription reﬁlls. Use of topical
corticosteroid therapy was associated with decrease in psoriasis-
speciﬁc health care costs (p = 0.022) and better health status (P
< 0.01). Increased ofﬁce based visits resulted in higher acne and
psoriasis related health care costs (p < 0.01). Increased number
of reﬁlls of acne speciﬁc drugs and oral contraceptive use was
associated with an improvement in health status (p < 0.05).
CONCLUSIONS: Use of controller medications in psoriasis,
most notably topical corticosteroids is the primary driver of
reduced health care costs and better health status. Contrary to
popular belief, pharmacological treatment of acne does not sig-
niﬁcantly add to acne-related health care costs.
PSK5
TREATMENT PATTERNS IN PATIENTS WITH SEVERE
PSORIASIS
Kulkarni AS1, Horn E2, Balkrishnan R1, Feldman SR3
1The Ohio State University College of Pharmacy, Columbus, OH,
USA, 2National Psoriasis Foundation, Portland, OR, USA, 3Wake
Forest University School of Medicine, Winston Salem, NC, USA
OBJECTIVES: This study examined if patients with severe pso-
riasis were treated in accordance with therapy/medications as per
guidelines recommended by the American Academy of Derma-
tology (AAD) (i.e. receive either phototherapy or systemic treat-
ment). METHODS: A survey for this study was conducted by
the National Psoriasis Foundation between November and
December 2004. Respondents, screened for a mix of gender and
age, were interviewed over the phone (n = 188) and by online
surveys (n = 212). Information on current medication use was
obtained. Self-reported Body Surface Area (BSA) involvement
was used to measure severity of psoriasis. BSA of greater than
10% is indicative of severe psoriasis. Severity was also assessed
more globally using the Koo-Mentor Psoriasis Index (KMPI).
KMPI scores of 50 and above are suggestive of signiﬁcant nega-
tive health related quality of life and warrant initiation of sys-
temic therapy. Cross sectional nature of this study permitted
analysis of patients with severe psoriasis only. Descriptive data
were generated to determine demographic characteristics of
study population and prescription patterns. RESULTS: Approx-
imately 55% of the population had severe psoriasis as measured
by BSA, while 75% had severe psoriasis as per KMPI scores.
About 19% of the study population indicated that they were cur-
rently not on any treatment. Almost 15% of the patients with
severe psoriasis identiﬁed with BSA (n = 212) and KMPI (n =
299) were on some form of topical therapy alone to treat their
psoriasis (i.e. they were not treated in accordance to the AAD
guidelines.). CONCLUSIONS: AAD guidelines provide a stan-
dard for psoriasis treatment options and conditions for their pre-
scriptions. Even with such easily accessible guidelines in place,
this study has shown that there are several people suffering from
severe psoriasis that are not on recommended therapy.
SKIN—Patient Reported Outcomes
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USING MEDIATION MODELS TO ASSESS THE INCREMENTAL
VALUE OF QUALITY OF LIFE QUESTIONNAIRES: DLQI IN
PSORIASIS
Bala M,Wu Y
Centocor Clinical Research and Development, Inc, Malvern, PA, USA
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OBJECTIVES: The objective of this analysis was to examine
whether the Dermatology Life Quality Index (DLQI) provided
any additional information beyond what is captured by the Pso-
riasis Areas and Severity Index (PASI) in psoriasis. METHODS:
The DLQI is used to assess Health-related Quality of Life
(HRQL) in psoriasis, with higher scores corresponding to worse
HRQL. The percent improvement in PASI is the key clinical
measure used to assess treatment effect in psoriasis. We used a
simple mediation model, used in social science to evaluate direct
and indirect effects. This model involves estimating the follow-
ing equations:DDLQI = i1 + A * treatment; DPASI = i2 + B *
treatment; DDLQI = i3 + C * DPASI + D * treatment. If A and
B are not signiﬁcant, mediation is not likely to exist. The indi-
rect effect of treatment on DDLQI (mediated by PASI) is given
by B*C. If D is signiﬁcant, DLQI provides additional informa-
tion beyond what is captured by PASI. We used data from two
large randomized, double-blind clinical trials, comparing inﬂix-
imab to placebo. The change from baseline to week 10 was used
to estimate the equations. RESULTS: A total of 1213 patients
were enrolled in the two trials. The regression estimates were:
DDLQI = -0.51 - 9.6a * treatment; DPASI = 7.52a + 73.98a *
treatment; DDLQI = 0.19 - 0.09a * DPASI - 2.73a * treatment.
The indirect effect was signiﬁcant. However, the direct treatment
effect on DLQI (not mediated by PASI) was also signiﬁcant.
CONCLUSIONS: The DLQI is a useful complement to PASI in
assessing psoriasis treatments, as it captures additional informa-
tion regarding treatment. Mediation analysis can be a useful
method to assess the incremental value of HRQL measures. ap <
0.05.
PSK7
SMOKING—Cost Studies
PSM1
POTENTIAL BENEFITS OF SMOKING CESSATION
TREATMENT COVERAGE AT THE WORKPLACE
Halpern MT1, Schmier JK1, Dirani RG2
1Exponent, Alexandria,VA, USA, 2Pﬁzer Inc, New York, NY, USA
OBJECTIVES: To demonstrate the potential beneﬁts of coverage
for pharmacologic smoking cessation treatments at the work-
place by evaluation of a cost of illness model. METHODS: A
cost of illness model utilizing a hypothetical cohort of 1000
employees was used to evaluate the impact of coverage versus
non-coverage of pharmacologic smoking cessation treatments in
the workplace represented by direct beneﬁts to employee health
and indirect beneﬁts to employers (decreased absenteeism and
increased productivity). Data were derived from a previously
published smoking cessation model with future costs and out-
comes discounted at 3% annually. RESULTS: By providing cov-
erage of pharmacologic smoking cessation treatments, the rate
of smoking cessation could increase by 5%, which translates to
almost an additional 100 of 1000 smokers quitting over a 10-
year period. This would have a direct impact on health care costs
due to the avoidance of various smoking-related illnesses, such
as heart disease, cerebrovascular disease, and lung cancer. In the
ﬁrst year following the initiation of coverage, direct savings on
health care costs is projected to be approximately $21,000. After
5 years, the savings increases to $231,000, and over 10 years, a
savings of $610,000 is projected. When indirect cost savings are
considered, the projected economic beneﬁt almost doubles. In the
ﬁrst year, health care cost savings increase to $41,000, and after
5 and 10 years, savings increase to $451,000 and $1.2 million,
respectively. If the rate of smoking cessation increased from 5%
to 10%, health care savings would increase to $41,000 after the
ﬁrst year and $1 million after 10 years. By incorporating indi-
rect cost savings, these numbers increase to $82,000 after the
ﬁrst year and $2 million after 10 years. CONCLUSION: This
cost of illness model demonstrates a potentially important
savings resulting from the provision of pharmacologic smoking
cessation treatment.
SMOKING—Methods and Concepts
PSM2
EFFECT OF SMOKING ON PERCEIVED HEALTH STATUS
Yaffe K
University of Arizona,Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to examine the
extent to which reported quality of life differs between smokers
and nonsmokers when other physical and mental health status
factors are controlled for. METHODS: Data from the 2003
Medical Expenditure Panel Survey was used. This dataset repre-
sents 290,604,436 non-institutionalized adults in the US, 22%
of which were smokers. Three initial logistic regressions were run
using smoking status as the dependent variable. The ﬁrst logis-
tic regression included demographics and education level as
explanatory variables; the second model included diagnosis-
related variables; and the last model considered other health-
related issues such as feeling calm and peaceful, having
functional limitations, etc. Variables signiﬁcantly associated with
smoking in the logistic regressions were used as covariates in a
linear regression with perceived health status as the dependent
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